SHANGHAI, 15. September 2025 /PRNewswire/ — Die EverBridge Group gab eine exklusive Vermarktungspartnerschaft mit Cosmotec Inc. (einer hundertprozentigen Tochtergesellschaft von M3, Inc.; TSE: 2413) für den japanischen Markt. Diese strategische Zusammenarbeit unterstreicht die führende Rolle der EverBridge Group in der firmeneigenen Forschung und Entwicklung, der strikten Einhaltung gesetzlicher Vorschriften und der wertorientierten Zusammenarbeit im Ökosystem… Continue reading EverBridge Group und Cosmotec schmieden bahnbrechende Partnerschaft
Author: PR Newswire Online News
Lion TCR Achieves Triple FDA Milestones with IND Clearance for Chronic Hepatitis B Following Earlier Fast Track and Orphan Drug Designations
SINGAPORE and GUANGZHOU, China, Sept. 14, 2025 /PRNewswire/ — Lion TCR, a clinical-stage biotechnology company pioneering T-cell receptor (TCR)-based therapies, today announced that it has received Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA) to initiate phase1b/2 clinical trials for its proprietary TCR-T cell therapy, LioCyx-M004, in patients with chronic hepatitis… Continue reading Lion TCR Achieves Triple FDA Milestones with IND Clearance for Chronic Hepatitis B Following Earlier Fast Track and Orphan Drug Designations
Phrontline Biopharma Announces First Patient Dosed in Phase 1 Clinical Trial of TJ101
SHANGHAI and SUZHOU, China, Sept. 14, 2025 /PRNewswire/ — Phrontline Biopharma, a clinical-stage biotechnology company advancing a new generation of Antibody-Drug Conjugates (ADCs), today announced that the first patient has been successfully dosed in its Phase 1 clinical trial of TJ101, the company’s lead asset targeting EGFR/B7-H3 with a proprietary linker-drug technology. “This is a critical milestone for… Continue reading Phrontline Biopharma Announces First Patient Dosed in Phase 1 Clinical Trial of TJ101
EverBridge Group et Cosmotec concluent un partenariat historique
SHANGHAI, 15 septembre 2025 /PRNewswire/ — EverBridge Group a annoncé un partenariat de commercialisation exclusif avec Cosmotec Inc. (une filiale à part entière de M3, Inc. ; TSE : 2413) pour le marché japonais. Cette collaboration stratégique souligne le leadership d’EverBridge Group en matière de R&D exclusive, de conformité réglementaire rigoureuse et de collaboration écosystémique… Continue reading EverBridge Group et Cosmotec concluent un partenariat historique
EverBridge Group y Cosmotec forjan una alianza histórica
SHANGHÁI, 15 de septiembre de 2025 /PRNewswire/ — EverBridge Group anunció una asociación de comercialización exclusiva con Cosmotec Inc. (una subsidiaria de propiedad absoluta de M3, Inc.; TSE: 2413) para el mercado japonés. Esta colaboración estratégica subraya el liderazgo de EverBridge Group en I+D patentada, un estricto cumplimiento normativo y una colaboración en un ecosistema… Continue reading EverBridge Group y Cosmotec forjan una alianza histórica
Lion TCR Achieves Triple FDA Milestones with IND Clearance for Chronic Hepatitis B Following Earlier Fast Track and Orphan Drug Designations
SINGAPORE and GUANGZHOU, China, Sept. 14, 2025 /PRNewswire/ — Lion TCR, a clinical-stage biotechnology company pioneering T-cell receptor (TCR)-based therapies, today announced that it has received Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA) to initiate phase1b/2 clinical trials for its proprietary TCR-T cell therapy, LioCyx-M004, in patients with chronic hepatitis… Continue reading Lion TCR Achieves Triple FDA Milestones with IND Clearance for Chronic Hepatitis B Following Earlier Fast Track and Orphan Drug Designations
Phrontline Biopharma Announces First Patient Dosed in Phase 1 Clinical Trial of TJ101
SHANGHAI and SUZHOU, China, Sept. 14, 2025 /PRNewswire/ — Phrontline Biopharma, a clinical-stage biotechnology company advancing a new generation of Antibody-Drug Conjugates (ADCs), today announced that the first patient has been successfully dosed in its Phase 1 clinical trial of TJ101, the company’s lead asset targeting EGFR/B7-H3 with a proprietary linker-drug technology. “This is a critical milestone for… Continue reading Phrontline Biopharma Announces First Patient Dosed in Phase 1 Clinical Trial of TJ101
EverBridge Group und Cosmotec schmieden bahnbrechende Partnerschaft
SHANGHAI, 15. September 2025 /PRNewswire/ — Die EverBridge Group gab eine exklusive Vermarktungspartnerschaft mit Cosmotec Inc. (einer hundertprozentigen Tochtergesellschaft von M3, Inc.; TSE: 2413) für den japanischen Markt. Diese strategische Zusammenarbeit unterstreicht die führende Rolle der EverBridge Group in der firmeneigenen Forschung und Entwicklung, der strikten Einhaltung gesetzlicher Vorschriften und der wertorientierten Zusammenarbeit im Ökosystem… Continue reading EverBridge Group und Cosmotec schmieden bahnbrechende Partnerschaft
EverBridge Group and Cosmotec Forge Landmark Partnership
SHANGHAI, Sept. 15, 2025 /PRNewswire/ — EverBridge Group announced an Exclusive Commercialization Partnership with Cosmotec Inc. (a Wholly Owned Subsidiary of M3, Inc.; TSE: 2413) for the Japanese market. This strategic collaboration underscores EverBridge Group’s leadership in proprietary R&D, stringent regulatory compliance, and value-driven ecosystem collaboration, marking a significant milestone in its global expansion strategy,… Continue reading EverBridge Group and Cosmotec Forge Landmark Partnership
Armor Health Announces Partnership with Antidote-AI to Revolutionize Correctional Healthcare Landscape
MIAMI, Sept. 14, 2025 /PRNewswire/ — Armor Health (ArmorHealthcare.com), today announced it’s new partnership with Antidote-AI (Antidote-AI.com) as their correctional healthcare technology partner to provide Armor with their powerful AI clinical tools, embedded in Armor’s Insights Analytics technology platform. Powered by Antidote’s AI solution, Armor’s Insights Analytics will tie in objective measures and integrate… Continue reading Armor Health Announces Partnership with Antidote-AI to Revolutionize Correctional Healthcare Landscape